InvestmentAug 5, 2026, 05:26 PM
Glucotrack Secures $5.5M Financing, Including $2M Equity & $3.5M Debt
AI Summary
Glucotrack, Inc. announced definitive agreements for approximately $5.5 million in financing from institutional investors. This financing package includes a $2.0 million equity financing priced at $0.75 per unit, with each unit comprising one common share and one five-year warrant. Additionally, it includes a $3.5 million follow-on investment in the form of senior secured convertible promissory notes. The company stated that this financing strengthens its balance sheet, provides additional growth capital, and reflects confidence in its long-term strategy.
Key Highlights
- Secured $5.5 million in total financing from institutional investors.
- Includes $2.0 million equity financing priced at $0.75 per unit.
- Equity units comprise one common share and one five-year warrant with a $1.50 exercise price.
- Includes $3.5 million follow-on investment via senior secured convertible promissory notes.
- Follow-On Bridge Notes have $3.5M principal, 22% OID, 8% interest, and 9-month maturity.
- Notes and warrants are convertible/exercisable pending stockholder approval.
- E.F. Hutton & Co. served as advisor to Glucotrack's subsidiary, Lōkahi Therapeutics.
- The financing strengthens the balance sheet and provides additional growth capital.
Price Impact
More from GCTK